NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial

NVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial

RTTNews

Published

Today's Daily Dose brings you news about encouraging results of Novavax' Covid-19 vaccine candidate; FDA lifting the clinical hold on Bellicum's BPX-601 study; and near-term catalysts of Ayala Pharma and AzurRx.

Full Article